Dry age-related macular degeneration market outlook with key growth drivers
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Dry Age Related Macular Degeneration (AMD) Market In 2026 And 2030?
The market size for dry age related macular degeneration (amd) has experienced robust growth in recent years. It is projected to expand from $4.89 billion in 2025 to $5.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Historically, this growth can be attributed to aging population growth, the expansion of ophthalmology clinics, the adoption of vitamin-based therapies, advancements in retinal imaging, and increased awareness of vision loss.
The market size for dry age related macular degeneration (AMD) is anticipated to show robust growth in the coming years. It is forecast to expand to $7.36 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.5%. This growth during the projection period can be attributed to the development of novel therapeutic pipelines, advancements in precision ophthalmology, the rise of AI-based retinal diagnostics, proactive eye care initiatives, and increased investments in clinical trials. Noteworthy trends anticipated during this period include a heightened focus on early disease detection, a greater adoption of nutritional supplement therapies, an expansion of research into disease-modifying drugs, increased utilization of advanced retinal imaging techniques, and improved patient awareness and screening efforts.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Key Factors Are Driving The Dry Age Related Macular Degeneration (AMD) Market Growth?
An expanding older adult demographic is anticipated to stimulate the advancement of the dry age-related macular degeneration (AMD) market in the future. This demographic comprises individuals aged 65 years and above, who undergo physiological shifts linked to aging, thereby raising their demand for healthcare and vision-care services. The increase in the geriatric population is attributable to longer life expectancies, enhanced management of chronic diseases, progress in medical technology, and broader availability of elder care globally. The dry age-related macular degeneration (AMD) market contributes to this progression by providing specialized treatments and management strategies designed to decelerate retinal degeneration and maintain sight in older individuals. As an illustration, data from the United Nations, a US-based intergovernmental organization, showed in July 2023 that the worldwide population aged 65 years and above reached 0.77 billion in 2022 and is forecasted to near 1.0 billion by 2030. Consequently, the increasing number of older adults is a key impetus for the expansion of the dry age-related macular degeneration (AMD) market.
What Are The Different Segment Types In The Dry Age Related Macular Degeneration (AMD) Market Segment Breakdown?
The dry age related macular degeneration (amd) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
Which Trends Are Guiding The Direction Of The Dry Age Related Macular Degeneration (AMD) Market?
Key companies within the dry age-related macular degeneration (AMD) market are prioritizing the creation of sophisticated technologies, including light delivery systems, aimed at activating retinal cells, improving visual capabilities, and potentially decelerating the disease’s advancement. Light delivery systems are defined as therapeutic instruments engineered to supply controlled light wavelengths to targeted retinal areas, stimulating cellular processes and maintaining retinal health via non-invasive photobiomodulation methods. An illustration of this occurred in January 2024, when LumiThera Inc., a US-based medical device firm, launched its photobiomodulation therapy for dry AMD, featuring the Valeda Light Delivery System, which stands as the first FDA-authorized treatment for vision loss linked to dry AMD. This particular system employs a multi-wavelength light application, utilizing 590 nm, 660 nm, and 850 nm wavelengths to stimulate retinal cells, and LumiThera has initiated the EUROLIGHT registry study to collect comprehensive long-term outcome data, with treatment protocols typically involving nine sessions spread across a three- to four-week period.
Who Are The Well-Known Companies In The Dry Age Related Macular Degeneration (AMD) Market?
Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.
Get The Full Dry Age Related Macular Degeneration (AMD) Market Report:
Which Region Is The Largest In The Dry Age Related Macular Degeneration (AMD) Market?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in the dry age related macular degeneration (amd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Dry Age Related Macular Degeneration (AMD) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Dry Age Related Macular Degeneration (AMD) Market 2026, By The Business Research Company
Non Proliferative Diabetic Retinopathy Market Report 2026
Macular Degeneration Treatment Market Report 2026
Macular Edema And Macular Degeneration Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
